← Back

Beijing Succeeder Technology Inc

Beijing Succeeder Technology Inc. researches, develops, produces, and sells testing instruments, reagents, and consumables for in vitro diagnostics in thrombosis and hemostasis. Its offerings include coagulation testers, hemorheology testers, erythrocyte sedimentation rate and hematocrit testers, platelet aggregation testers, blood rheology analyzers, diagnostic reagents, quality control products, and automated equipment with supporting testing instruments. These products are used in the prevention, screening, diagnosis, and monitoring of thrombophilia and hemorrhagic diseases such as stroke, coronary heart disease, and venous thromboembolism. Founded in 2003, the company is based in Beijing, China, and operates domestically and internationally.

Price · split & dividend adjusted
News & notes moving 688338.CG
688338.CG2

Saike Xide's 2026 interim report shows net profit of 42.52 million yuan, down 11.41% year-on-year

Saike Xide released its 2026 interim report, with net profit attributable to the parent company of 42.52 million yuan, a decrease of 11.41% compared with the same period last year. The company's total operating revenue was 133 million yuan, a decrease of 5.9957 million yuan from the same period last year, down 4.31% year-on-year. Net cash inflow from operating activities was 37.97 million yuan. The latest asset-liability ratio was 3.73%, gross margin was 62.26%, and diluted earnings per share was 0.41 yuan.
Jiemian·26dRead more →
688338.CG

Succeeder Technology first-half net profit 42.52 million yuan, down 11.41% year on year

Succeeder Technology disclosed its 2026 half-year report. In the first half, it achieved operating revenue of 133 million yuan, down 4.31% year on year. Net profit attributable to shareholders of the listed company was 42.52 million yuan, down 11.41% year on year. Basic earnings per share were 0.41 yuan. The company said the decline was mainly affected by a combination of factors, including medical institutions strengthening management of test item packages, DRG and DIP payment reform, and mutual recognition of test results.
证券时报·29dRead more →